Literature DB >> 9641186

Adding plasmapheresis to corticosteroids and alkylating agents: does it benefit patients with focal segmental glomerulosclerosis?

A H Mitwalli1.   

Abstract

DESIGN: Eleven adult patients with biopsy-proven primary FSGS and nephrotic syndrome resistant to steroids and cytotoxic drugs were treated with plasmapheresis in addition to oral prednisolone and intravenous cyclophosphamide. On the average each patient had undergone 17 sessions over a period of 15-25 weeks (mean 21.90+/-2.71 weeks).
RESULTS: One month after the last plasmapheresis session, 72.7% (n=8) of the patients were in clinical remission of nephrotic syndrome in association with the stabilization of renal function. In contrast, patients who did not respond 27.3% (n=3) had a gradual decline in renal function. After a mean follow-up of 27.45+/-6.31 months, six patients who responded (54.5%) remained in sustained complete or partial remission of proteinuria with stable renal function. The mean proteinuria at the latest examination was 0.9+/-0.01 g per day in these patients.
CONCLUSION: It is concluded that a combination of plasmapheresis, corticosteroids, and cyclophosphamide may obtain sustained improvement of proteinuria and stabilization of plasma creatinine in about half of the patients who proved to be refractory to therapy.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9641186     DOI: 10.1093/ndt/13.6.1524

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  7 in total

Review 1.  Available and incoming therapies for idiopathic focal and segmental glomerulosclerosis in adults.

Authors:  Mirco Belingheri; Gabriella Moroni; Piergiorgio Messa
Journal:  J Nephrol       Date:  2017-05-03       Impact factor: 3.902

Review 2.  Therapeutic apheresis in kidney diseases: an updated review.

Authors:  Yi-Yuan Chen; Xin Sun; Wei Huang; Fang-Fang He; Chun Zhang
Journal:  Ren Fail       Date:  2022-12       Impact factor: 3.222

3.  Tacrolimus therapy in pediatric patients with treatment-resistant nephrotic syndrome.

Authors:  Kim Loeffler; Manjula Gowrishankar; Verna Yiu
Journal:  Pediatr Nephrol       Date:  2004-02-03       Impact factor: 3.714

4.  Abatacept experience in steroid and rituximab-resistant focal segmental glomerulosclerosis.

Authors:  Vinothkumar Kavarthapol Jayaraman; Mark Thomas
Journal:  BMJ Case Rep       Date:  2016-02-17

5.  Clinical practice guideline for pediatric idiopathic nephrotic syndrome 2013: medical therapy.

Authors:  Kenji Ishikura; Shinsuke Matsumoto; Mayumi Sako; Kazushi Tsuruga; Koichi Nakanishi; Koichi Kamei; Hiroshi Saito; Shuichiro Fujinaga; Yuko Hamasaki; Hiroko Chikamoto; Yasufumi Ohtsuka; Yasuhiro Komatsu; Toshiyuki Ohta; Takuhito Nagai; Hiroshi Kaito; Shuji Kondo; Yohei Ikezumi; Seiji Tanaka; Yoshitsugu Kaku; Kazumoto Iijima
Journal:  Clin Exp Nephrol       Date:  2015-02       Impact factor: 2.617

Review 6.  Therapeutic approach to FSGS in children.

Authors:  Debbie S Gipson; Keisha Gibson; Patrick E Gipson; Sandra Watkins; Marva Moxey-Mims
Journal:  Pediatr Nephrol       Date:  2006-11-16       Impact factor: 3.714

Review 7.  Treatment Strategies of Adult Primary Focal Segmental Glomerulosclerosis: A Systematic Review Focusing on the Last Two Decades.

Authors:  Arno Beer; Gert Mayer; Andreas Kronbichler
Journal:  Biomed Res Int       Date:  2016-04-07       Impact factor: 3.411

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.